why choose us

First received: January 20, 2023

Clinical Trial: Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study

Study Status: Completed

Recruit Status: RECRUITING

Condition: Chronic Lymphocytic Leukemia

Study Type: INTERVENTIONAL


Official Title: A Phase 2 Study With a Safety Lead-In of the Anti-CD19 Antibody Tafasitamab With the BTK Inhibitor Zanubrutinib in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL

Brief Summary: This phase II trial tests how well tafasitamab and zanubrutinib works in treating patients with newly diagnosed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).Tafasitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread.Zanubrutinib is in a class of medications called kinase inhibitors.It works by blocking the action of a protein that signals cancer cells to multiply.This may stop the growth and spread of cancer cells.Giving tafasitamab and…

Read more